Skip to main content

Advertisement

SpringerLink
Log in

Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914–25. doi:10.1016/S1474-4422(15)00111-8.

    Article  PubMed  Google Scholar 

  2. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506. doi:10.1200/JCO.2012.42.8201.

    Article  CAS  Google Scholar 

  3. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500. doi:10.1056/NEJM199602223340803.

    Article  CAS  PubMed  Google Scholar 

  4. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. Am J Neuroradiol. 2007;28(7):1320–7. doi:10.3174/ajnr.A0549.

    Article  CAS  PubMed  Google Scholar 

  5. Kamiya-Matsuoka C, Paker AM, Chi L, et al. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neuro-Oncol. 2016;128(1):75–84. doi:10.1007/s11060-016-2078-0.

    Article  Google Scholar 

  6. Lamy C, Oppenheim C, Mas JL. Posterior reversible encephalopathy syndrome. Handb Clin Neurol. 2014;121:1687–701. doi:10.1016/B978-0-7020-4088-7.00109-7.

    Article  CAS  PubMed  Google Scholar 

  7. Miaris N, Maltezou M, Papaxoinis G, et al. Posterior reversible encephalopathy syndrome with concurrent nephrotic syndrome in a patient treated with pazopanib for metastatic renal cell carcinoma: case report and review of the literature. Clin Genitourin Cancer. 2017; doi:10.1016/j.clgc.2016.08.005.

  8. Tlemsani C, Mir O, Boudou-Rouquette P, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol. 2011;6(4):253–8. doi:10.1007/s11523-011-0201-x.

    Article  PubMed  Google Scholar 

  9. Granata G, Greco A, Iannella G, et al. Posterior reversible encephalopathy syndrome—insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2015;14(9):830–6. doi:10.1016/j.autrev.2015.05.006.

    Article  CAS  PubMed  Google Scholar 

  10. How J, Blattner M, Fowler S, et al. Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature. Neurologist 2016;21(6):112–7. doi:10.1097/NRL.0000000000000105.

  11. Myint ZW, Sen JM, Watts NL, et al. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature Review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors. Clin Colorectal Cancer. 2017;13(2):127–30. doi:10.1016/j.clcc.2013.12.003.

    Article  Google Scholar 

  12. Truman N, Nethercott D. Posterior reversible encephalopathy syndrome (PRES) after treatment with oxaliplatin and 5-fluorouracil. Clin Colorectal Cancer. 2013;12(1):70–2. doi:10.1016/j.clcc.2012.06.003.

    Article  PubMed  Google Scholar 

  13. Dedić Plavetić N, Rakušić Z, Ozretić D, et al. Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen. World J Surg Oncol. 2014;12(1):264. doi:10.1186/1477-7819-12-264.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63(10):1475–8. doi:10.1001/archneur.63.10.1475.

    Article  PubMed  Google Scholar 

  15. Singer S, Grommes C, Reiner AS, et al. Posterior reversible encephalopathy syndrome in patients with cancer. Oncologia. 2015;20:806–11. doi:10.1634/theoncologist.2014-0149.

    Article  Google Scholar 

  16. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci. 2002;99(17):11393–8. doi:10.1073/pnas.172398299.

    Article  CAS  PubMed  Google Scholar 

  17. Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res. 2013;19(8):1920–5. doi:10.1158/1078-0432.CCR-12-2911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Chen H, Modiano MR, Neal JW, et al. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer. 2014;110(3):602–8. doi:10.1038/bjc.2013.735.

    Article  CAS  PubMed  Google Scholar 

  19. Leighl NB, Raez LE, Besse B, et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol. 2010;5(7):1054–9. doi:10.1097/JTO.0b013e3181e2f7fb.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Third Department of Medical Oncology, ‘Agioi Anargyroi’ General Oncology Hospital of Kifisia, Noufaron and Timiou Stavrou 14, N. Kifisia, 14564, Athens, Greece

    Nikolaos Miaris, Joseph Sgouros, Margarita Gerolympou, Stefania Gkoura, Helen Res & Epaminondas Samantas

  2. First Department of Internal Medicine, 401 General Military Hospital of Athens, Athens, Greece

    Basilios Spyropoulos

  3. Department of Radiology, 401 General Military Hospital of Athens, Athens, Greece

    Dionysios Drakopoulos

Authors
  1. Nikolaos Miaris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Sgouros
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Margarita Gerolympou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Basilios Spyropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dionysios Drakopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stefania Gkoura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Helen Res
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Epaminondas Samantas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nikolaos Miaris.

Ethics declarations

Informed Consent

Informed consent was obtained from the patient for publication of this manuscript and any accompanying images.

Conflict of Interest

The authors declare that they have no competing interests.

Financial Support

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miaris, N., Sgouros, J., Gerolympou, M. et al. Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer. J Gastrointest Canc 50, 123–126 (2019). https://doi.org/10.1007/s12029-017-9986-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-017-9986-x

Keywords

Search

Navigation